不可分类间质性肺疾病的免疫调节治疗:一项回顾性治疗反应研究
混合效应线性回归和倾向性评分匹配分析均显示,治疗与未治疗患者间FVC和DLco的下降速率差异无统计学意义,提示免疫调节治疗总体无额外获益。
要点
- 治疗组基线FVC和DLco更低,提示病情更重。
- 校正分析显示治疗与未治疗患者肺功能下降速率差异无统计学意义。
- 部分患者可能从免疫调节治疗中获得改善或稳定,需前瞻性研究识别获益亚组。
核心结论
- 治疗与未治疗患者的肺功能轨迹平行,尽管治疗组基线病情更重。
- 组间持续差异提示免疫调节治疗总体无额外效果,但部分患者可能改善或稳定。
研究设计与样本
- 回顾性研究,在两家ILD中心纳入249例不可分类ILD患者。
- 采用混合效应线性回归模型(含或不含临床协变量)及基于性别、年龄、GAP分期、吸烟和磨玻璃影的倾向性评分匹配分析。
主要发现
- 治疗组基线FVC占预计值72%,未治疗组83%;DLco占预计值44% vs 60%。
- 混合效应线性回归中,FVC调整后变化为-0.22% [-0.34; -0.11],DLco为-0.15% [-0.28; -0.012]。
- 治疗与未治疗患者FVC下降差异为-0.082%/月 [-0.28; 0.11],p=0.10;DLco差异为-0.14%/月 [-0.36; 0.079],p=0.15。
- 倾向性评分匹配分析中,FVC变化差异为0.039%/月,p=0.12;DLco变化差异为0.0085%/月,p=0.7。
临床怎么用
- 对不可分类ILD患者启动免疫调节治疗前应充分评估,总体获益不明确。
- 治疗决策需个体化,密切监测肺功能轨迹以识别可能获益的患者。
局限性
- 回顾性研究设计,存在选择偏倚和混杂因素。
- 治疗组基线病情更重,可能影响治疗效果的评估。
- 样本来自两家中心,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The optimal management of unclassifiable Interstitial lung disease (ILD) remains a challenge. The aim of this study was to describe pulmonary function trajectories for patients treated with immunomodulatory therapy and for untreated patients. METHODS: Clinical information and treatment data were obtained retrospectively at two ILD centres. Pulmonary function data were analysed using (1) mixed effects linear regression models with and without clinical covariates and (2) propensity score matching using gender, age, physiology (GAP) stage, smoking and presence of ground glass opacities. RESULTS: Sixty-five percent of the 249 patients included received corticosteroids and/or other immunomodulators. Treated patients had lower forced vital capacity (FVC) (72% vs. 83% predicted) and diffusing capacity for carbon monoxide (DLco) (44% vs. 60% predicted). In mixed effects linear regression, the adjusted change in FVC was -0.22%, [-0.34; -0.11], and -0.15% [-0.28;-0.012] for DLco. The difference in pulmonary function decline between treated and untreated patients was insignificant, -0.082% per month, [-0.28; 0.11], p = 0.10 for FVC and -0.14% per month, [-0.36; 0.079], p = 0.15, for DLco. In propensity score matched analysis, the difference in change in FVC was 0.039% per month, p = 0.12, and for DLco, 0.0085% per month, p = 0.7. CONCLUSION: The pulmonary function trajectories for treated and untreated patients were parallel, despite treated patients having more severe disease at baseline. The persisting differences between the groups suggest no overall effect, although improvement or stabilization may be seen in some patients. Prospective studies are needed to define subsets of patients with unclassifiable interstitial lung disease and their optimal management.
引用
- Hyldgaard C, Torrisi S, Kronborg Brix-White S, et al. Immunomodulatory treatment in unclassifiable interstitial lung disease: A retrospective study of treatment response. Respirology. 2022. PMID: 36372786. doi:10.1111/resp.14409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。